Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913584 | 1.00 | LMNA (0.33) | LMNA | |
| SCHEMBL2519794 | 0.72 | LMNA (0.46) | LMNA | |
| SCHEMBL3164776 | 0.71 | ALDH1A1 (0.42) | LMNA | |
| SCHEMBL16503656 | 0.69 | — | — | |
| SCHEMBL3268163 | 0.69 | — | — | |
| SCHEMBL4196109 | 0.69 | — | — | |
| SCHEMBL422869 | 0.67 | — | — | |
| SCHEMBL4033001 | 0.67 | — | — | |
| SCHEMBL8932212 | 0.67 | — | — | |
| SCHEMBL293861 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | claimed |
| EP-1416929-A4 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | LU ZHIMIN (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | claimed |
| EP-1416929-A2 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | Lu, Zhimin (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003009809-A2 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | LU ZHIMIN (US) | 2003-02-06 | — | — | WO | claimed |
| US-20020016352-A1 | Cancer treatment with Go6976 and its related compounds | LU ZHIMIN (US) | 2002-02-07 | — | — | US | claimed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | claimed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | claimed |
| US-5489608-A | FOR TREATMENT OF HEART AND BLOOD VESSEL DISEASES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | claimed |
| WO-1993024490-A1 | USE OF INDOLOCARBAZOLS IN AIDS TREATMENT | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | claimed |
| EP-0434057-A2 | Indolocarbazole derivatives, processes for their preparation and their use | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | claimed |
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | disclosed |
| EP-1416929-A4 | CANCER TREATMENT WITH GÖ6976 AND ITS RELATED COMPOUNDS | LU ZHIMIN (US) | 2007-05-23 | — | — | EP | disclosed |
| CN-1274303-C | Application of compound and derivative thereof in preparation of medicine for preventing and treating cancer | LU ZHIMIN (CN) | 2006-09-13 | — | — | CN | disclosed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | disclosed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| US-5489608-A | FOR TREATMENT OF HEART AND BLOOD VESSEL DISEASES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | disclosed |
| WO-1993024490-A1 | USE OF INDOLOCARBAZOLS IN AIDS TREATMENT | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | disclosed |
| EP-0434057-A2 | Indolocarbazole derivatives, processes for their preparation and their use | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | LMNA 1038/4885 |
| US-20020016352-A1 | Cancer treatment with Go6976 and its related compounds | GRK6, GALK1, PRKACA | LMNA 2580/4885 |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | LMNA 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.